Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Resistance of high fitness hepatitis C virus to lethal mutagenesis

  • Gallego, Isabel
  • Gregori, Josep
  • Soria, María Eugenia
  • García-Crespo, Carlos
  • García-Álvarez, Mónica
  • Gómez-González, Alfonso
  • Valiergue, Rosalie
  • Gómez-Castilla, Jordi
  • Esteban, Juan Ignacio
  • Quer, Josep
  • Domingo, Esteban
  • Perales, Celia
Viral fitness quantifies the degree of virus adaptation to a given environment. How viral fitness can influence the mutant spectrum complexity of a viral quasispecies subjected to lethal mutagenesis has not been investigated. Here we document that two high fitness hepatitis C virus populations display higher resistance to the mutagenic nucleoside analogues favipiravir and ribavirin than their parental, low fitness HCV. All populations, however, exhibited a mutation transition bias indicative of active mutagenesis. Resistance to the analogues was associated with a limited expansion of mutant spectrum complexity, as evidenced by several diversity indices used to characterize mutant spectra. The results are consistent with a replicative site-drug competition mechanism that was previously proposed for HCV fitness-associated resistance to non-mutagenic inhibitors. Other alternative, non-mutually exclusive mechanisms are considered. The results introduce viral fitness as a relevant parameter to evaluate the response of viruses to lethal mutagenesis, with implications for antiviral designs., We thank Dr. Charles M. Rice for the supply of plasmid Jc1FLAG2(p7-nsGluc2A) and helpful advice for the implement of HCV replicon in cell culture, and to Mercedes Guerrero for help with the statistics. Work in Barcelona was funded by Instituto de Salud Carlos III, by grants PI13/00456, PI15/00829, and PI16/00337 cofinanced by the European Regional Development Fund (ERDF), and by CDTI (Centro para el Desarrollo Tecnologico Industrial), Spanish Ministry of Economics and Competitiveness (MINECO), IDI-20151125. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121) cofinanced by the European Regional Development Fund (ERDF). CIBERehd (Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas) is funded by Instituto de Salud Carlos III. The work in Madrid was supported by grants BFU-2011-23604, SAF2014-52400-R, SAF2017-87846-R by Spanish MINECO and S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER). Institutional grants from the Fundacion Ramon Areces and Banco Santander to the CBMSO are also acknowledged.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

  • Chen, Q.
  • Perales, C.
  • Soria, M.E.
  • García-Cehic, D.
  • Gregori, J.
  • Rodríguez-Frías, F.
  • Buti, M.
  • Crespo, J.
  • Calleja, J.L.
  • Tabernero, D.
  • Vila, M.
  • Lázaro, F.
  • Rando-Segura, A.
  • Nieto-Aponte, L.
  • Llorens-Revull, M.
  • Cortese, M.F.
  • Fernandez-Alonso, I.
  • Castellote, J.
  • Niubó, J.
  • Imaz, A.
  • Xiol, X.
  • Castells, L.
  • Riveiro-Barciela, M.
  • Llaneras, J.
  • Navarro, J.
  • Vargas-Blasco, V.
  • Augustin, S.
  • Conde, I.
  • Rubín, Á.
  • Prieto, M.
  • Torras, X.
  • Margall, N.
  • Forns, X.
  • Mariño, Z.
  • Lens, S.
  • Bonacci, M.
  • Pérez-del-Pulgar, S.
  • Londoño, M.C.
  • García-Buey, M.L.
  • Sanz-Cameno, P.
  • Morillas, R.
  • Martró, E.
  • Saludes, V.
  • Masnou-Ridaura, H.
  • Salmerón, J.
  • Quíles, R.
  • Carrión, J.A.
  • Forné, M.
  • Rosinach, M.
  • Fernández, I.
  • García-Samaniego, J.
  • Madejón, A.
  • Castillo-Grau, P.
  • López-Núñez, C.
  • Ferri, M.J.
  • Durández, R.
  • Sáez-Royuela, F.
  • Diago, M.
  • Gimeno, C.
  • Medina, R.
  • Buenestado, J.
  • Bernet, A.
  • Turnes, J.
  • Trigo-Daporta, M.
  • Hernández-Guerra, M.
  • Delgado-Blanco, M.
  • Cañizares, A.
  • Arenas, J.I.
  • Gomez-Alonso, M.J.
  • Rodríguez, M.
  • Deig, E.
  • Olivé, G.
  • Río, O.D.
  • Cabezas, J.
  • Quiñones, I.
  • Roget, M.
  • Montoliu, S.
  • García-Costa, J.
  • Force, L.
  • Blanch, S.
  • Miralbés, M.
  • López-de-Goicoechea, M.J.
  • García-Flores, A.
  • Saumoy, M.
  • Casanovas, T.
  • Baliellas, C.
  • Gilabert, P.
  • Martin-Cardona, A.
  • Roca, R.
  • Barenys, M.
  • Villaverde, J.
  • Salord, S.
  • Camps, B.
  • Silvan di Yacovo, M.
  • Ocaña, I.
  • Sauleda, S.
  • Bes, M.
  • Carbonell, J.
  • Vargas-Accarino, E.
  • Ruzo, S.P.
  • Guerrero-Murillo, M.
  • Von Massow, G.
  • Costafreda, M.I.
  • López, R.M.
  • González-Moreno, L.
  • Real, Y.
  • Acero-Fernández, D.
  • Viroles, S.
  • Pamplona, X.
  • Cairó, M.
  • Ocete, M.D.
  • Macías-Sánchez, J.F.
  • Estébanez, A.
  • Quer, J.C.
  • Mena-de-Cea, Á.
  • Otero, A.
  • Castro-Iglesias, Á.
  • Suárez, F.
  • Vázquez, Á.
  • Vieito, D.
  • López-Calvo, S.
  • Vázquez-Rodríguez, P.
  • Martínez-Cerezo, F.J.
  • Rodríguez, R.
  • Macenlle, R.
  • Cachero, A.
  • Mereish, G.
  • Mora-Moruny, C.
  • Fábregas, S.
  • Sacristán, B.
  • Albillos, A.
  • Sánchez-Ruano, J.J.
  • Baluja-Pino, R.
  • Fernández-Fernández, J.
  • González-Portela, C.
  • García-Martin, C.
  • Sánchez-Antolín, G.
  • Andrade, R.J.
  • Simón, M.A.
  • Pascasio, J.M.
  • Romero-Gómez, M.
  • Antonio del-Campo, J.
  • Domingo, E.
  • Esteban, R.
  • Esteban, J.I.
  • Quer, J.
A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize the resistance profile of a large cohort of patients failing DAA-based treatments, and investigate the relationship between HCV subtype and failure, as an aid to optimizing management of these patients. A new, standardized HCV-RAS testing protocol based on deep sequencing was designed and applied to 220 previously subtyped samples from patients failing DAA treatment, collected in 39 Spanish hospitals. The majority had received DAA-based interferon (IFN) a-free regimens; 79% had failed sofosbuvir-containing therapy. Genomic regions encoding the nonstructural protein (NS) 3, NS5A, and NS5B (DAA target regions) were analyzed using subtype-specific primers. Viral subtype distribution was as follows: genotype (G) 1, 62.7%; G3a, 21.4%; G4d, 12.3%; G2, 1.8%; and mixed infections 1.8%. Overall, 88.6% of patients carried at least 1 RAS, and 19% carried RAS at frequencies below 20% in the mutant spectrum. There were no differences in RAS selection between treatments with and without ribavirin. Regardless of the treatment received, each HCV subtype showed specific types of RAS. Of note, no RAS were detected in the target proteins of 18.6% of patients failing treatment, and 30.4% of patients had RAS in proteins that were not targets of the inhibitors they received. HCV patients failing DAA therapy showed a high diversity of RAS. Ribavirin use did not influence the type or number of RAS at failure. The subtype-specific pattern of RAS emergence underscores the importance of accurate HCV subtyping. The frequency of “extra-target” RAS suggests the need for RAS screening in all three DAA target regions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice, Comparison with Massive Sequencing

  • Nieto, Leonardo|||0000-0002-1336-5645
  • Quer, Josep|||0000-0003-0014-084X
  • Ruiz-Ripa, Alicia
  • Tabernero, David|||0000-0002-1146-4084
  • González, Carolina|||0000-0002-0169-5874
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Vila, Marta|||0000-0001-9303-5189
  • Asensio, Miriam
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Ruiz, Gerardo
  • Chen, Qian
  • Ordeig, Laura
  • Llorens, Meritxell
  • Saez, Montserrat
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The unequivocal identification of hepatitis C virus (HCV) subtypes 1a/1b and genotypes 2 to 6 is required for optimizing the effectiveness of interferon-free, direct-acting antiviral therapies. We compared the performance of a new real-time HCV genotyping assay used on the Cobas 4800 system (C4800) with that of high-resolution HCV subtyping (HRCS). In total, 502 samples were used, including 184 samples from chronic HCV patients (from routine laboratory activity during April 2016), 5 stored samples with double HCV genotype infections for testing the limitations of the method, and 313 samples from a screening protocol implemented in our hospital (from May to August 2016) based on the new method to further determine its genotyping accuracy. A total of 282 samples, including 171 from April 2016 (the 13 remaining had too low of a viral load for HRCS), 5 selected with double infections, and 106 from screening, were analyzed by both methods, and 220 were analyzed only by the C4800. The C4800 correctly subtyped 125 of 126 1a/1b samples, and the 1 remaining sample was reported as genotype 1. The C4800 correctly genotyped 38 of 45 non-1a/1b samples (classified by HRCS), and it reported the remaining 7 samples as indeterminate. One hundred two of 106 non-1a/1b genotype samples that were identified using the C4800 for screening were confirmed by HRCS. In the 4 remaining samples, 3 were correctly reported as genotype 1 (without defining the subtype) and 1 was reported as indeterminate. None of the samples were misgenotyped. Four of 7 samples with double HCV infections were correctly genotyped by the C4800. Excluding the 5 selected double-infected samples, the C4800 showed 95.7% concordant results for genotyping HCVs 2 to 6 and 1a/1b subtyping, and 99.2% concordance for subtyping 1a/1b single infections in clinical samples. To improve laboratory workflow, we propose using the C4800 as a first-line test for HCV genotyping and 1a/1b classification, followed by transferring non-1a/1b samples to a center where HRCS is available, if further characterization is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Chen, Qian
  • Soria, Maria Eugenia
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Nieto, Leonardo|||0000-0002-1336-5645
  • Castells, Lluís|||0000-0002-6672-5931
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Domingo, Esteban
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
Controversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment. Resistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS). We have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Co-selection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients, Implications for immunization policies

  • Sabrià, Aurora
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Guix, Susana|||0000-0002-1588-3198
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Manzanares-Laya, Sandra
  • Caylà, Joan A.|||0000-0003-3891-111X
  • Bosch Navarro, Albert|||0000-0002-8111-9059
  • Quer, Josep|||0000-0003-0014-084X
  • Pintó, Rosa M.|||0000-0003-1382-6648
A huge outbreak in the men-having-sex-with-men (MSM) has hit Europe during the years 2016-2018. Outbreak control has been hampered by vaccine shortages in many countries, and to minimize their impact, reduction of antigen doses has been implemented. However, these measures may have consequences on the evolution of hepatitis A virus (HAV), leading to the emergence of antigenic variants. Cases in vaccinated MSM patients have been detected in Barcelona, opening the possibility to study HAV evolution under immune pressure. We performed deep-sequencing analysis of ten overlapping fragments covering the complete capsid coding region of HAV. A total of 14578255 reads were obtained and used for the analysis of virus evolution in vaccinated versus non-vaccinated patients. We estimated maximum and minimum mutation frequencies, and Shannon entropy in the quasispecies of each patient. Non-synonymous (NSyn) mutations affecting residues exposed in the capsid surface were located, with respect to epitopes, using the recently described crystal structure of HAV, as an indication of its potential role in escaping to the effect of vaccines. HAV evolution at the quasispecies level, in non-vaccinated and vaccinated patients, revealed higher diversity in epitope-coding regions of the vaccinated group. Although amino acid replacements occurring in and around the epitopes were observed in both groups, their abundance was significantly higher in the quasispecies of vaccinated patients, indicating ongoing processes of fixation. Our data suggest positive selection of antigenic variants in some vaccinated patients, raising concerns for new vaccination polices directed to the MSM group.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

  • von Massow, Georg
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Macià, María Dolores
  • Escarda, Ana
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of intra- and inter-host norovirus P2 genetic variability in linked individuals by amplicon sequencing

  • Sabrià, Aurora
  • Pintó, Rosa M.|||0000-0003-1382-6648
  • Bosch Navarro, Albert|||0000-0002-8111-9059
  • Quer, Josep|||0000-0003-0014-084X
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Domínguez, Ángela|||0000-0003-0219-1907
  • Carol Torrades, Monica
  • Sala-Farré, Maria Rosa
  • Guix, Susana|||0000-0002-1588-3198
Noroviruses are the main cause of epidemics of acute gastroenteritis at a global scale. Although chronically infected immunocompromised individuals are regarded as potential reservoirs for the emergence of new viral variants, viral quasispecies distribution and evolution patterns in acute symptomatic and asymptomatic infections has not been extensively studied. Amplicons of 450 nts from the P2 coding capsid domain were studied using next-generation sequencing (454/GS-Junior) platform. Inter-host diversity between symptomatic and asymptomatic acutely infected individuals linked to the same outbreak as well as their viral intra-host diversity over time were characterized. With an average of 2848 reads per sample and a cutoff frequency of 0.1%, minor variant haplotypes were detected in 5 out of 8 specimens. Transmitted variants could not be confirmed in all infected individuals in one outbreak. The observed initial intra-host viral diversity in asymptomatically infected subjects was higher than in symptomatic ones. Viral quasispecies evolution over time within individuals was host-specific, with an average of 2.8 nt changes per day (0.0062 changes per nucleotide per day) in a given symptomatic case. Nucleotide polymorphisms were detected in 28 out of 450 analyzed nucleotide positions, 32.14% of which were synonymous and 67.86% were non-synonymous. Most observed amino acid changes emerged at or near blockade epitopes A, B, D and E. Our results suggest that acutely infected individuals, even in the absence of symptoms, which go underreported and may enhance transmission, may contribute to norovirus genetic variability and evolution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus

  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Chen, Qian
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Llorens, Meritxell
  • de Ávila, Ana Isabel
  • Beach, Nathan M.
  • Domingo, Esteban
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban, Rafael|||0000-0001-5280-392X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5-10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017). The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 were tested to amplify NS3, NS5A-, and NS5B-coding regions in a subtype-specific manner, (ii) to define a reference sequence for each subtype, (iii) to perform experimental controls to define a cut-off value for detection of minority amino acids, (iv) to establish bioinformatics' tools to quantify amino acid replacements, and (v) to validate the procedure with patient samples. A robust ultra-deep sequencing procedure to analyze HCV circulating in serum samples from patients infected with virus that belongs to the ten most prevalent subtypes worldwide: 1a, 1b, 2a, 2b, 2c, 2j, 3a, 4d, 4e, 4f has been developed. Oligonucleotide primers are subtype-specific. A cut-off value of 1% mutant frequency has been established for individual mutations and haplotypes. The methodological pipeline described here is adequate to characterize in-depth mutant spectra of HCV populations, and it provides a tool to understand HCV diversification and treatment failures. The pipeline can be periodically extended in the event of HCV diversification into new genotypes or subtypes, and provides a framework applicable to other RNA viral pathogens, with potential to couple detection of drug-resistant mutations with treatment planning. The online version of this article (10.1186/s12879-018-3356-6) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare haplotype load as marker for lethal mutagenesis

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gallego, Isabel
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Domingo, Esteban
RNA viruses replicate with a template-copying fidelity, which lies close to an extinction threshold. Increases of mutation rate by nucleotide analogues can drive viruses towards extinction. This transition is the basis of an antiviral strategy termed lethal mutagenesis. We have introduced a new diversity index, the rare haplotype load (RHL), to describe NS5B (polymerase) mutant spectra of hepatitis C virus (HCV) populations passaged in absence or presence of the mutagenic agents favipiravir or ribavirin. The increase in RHL is more prominent in mutant spectra whose expansions were due to nucleotide analogues than to multiple passages in absence of mutagens. Statistical tests for paired mutagenized versus non-mutagenized samples with 14 diversity indices show that RHL provides consistently the highest standardized effect of mutagenic treatment difference for ribavirin and favipiravir. The results indicate that the enrichment of viral quasispecies in very low frequency minority genomes can serve as a robust marker for lethal mutagenesis. The diagnostic value of RHL from deep sequencing data is relevant to experimental studies on enhanced mutagenesis of viruses, and to pharmacological evaluations of inhibitors suspected to have a mutagenic activity.